A novel insulin sensitizer (S15511) enhances insulin-stimulated glucose uptake in rat skeletal muscles

Hormone and Metabolic Research

Volumn 40, Issue 4, 2008, Pages 269-275

  Jessen, N ^a   Selmer Buhl, E ^a,b   Pold, R ^a,b   Schmitz, O ^a,b   Lund, S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

GLUT4; Insulin sensitivity; Insulin sensitizer; Insulin signaling; Skeletal muscle; Type 2 diabetes; Wistar rat

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN; INSULIN; INSULIN SENSITIZING AGENT; S 15511; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; INSULIN SENSITIVITY; MALE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 3-O-METHYLGLUCOSE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPOSE TISSUE; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BODY WEIGHT; FLUORENES; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; GLYCOGEN; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MUSCLE, SKELETAL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 42149192520     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1022546     Document Type: Article

References (36)

1. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-797
2. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000; 23: 1278-1283
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
6. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150-1156
7. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077
8. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised control-led trial. Lancet 2006; 368: 1096-1105
9. Knowler WC, Narayan KM, Hanson RL, Nelson RG, Bennett PH, Tuomilehto J, Schersten B, Pettitt DJ. Preventing non-insulin-dependent diabetes. Diabetes 1995; 44: 483-488
10. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, Shulman GI. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999; 341: 240-246
11. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113: 909-915
12. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-4067
13. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 2002; 51: 443-448
14. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 176-185
15. Kubo K, Foley JE. Rate-limiting steps for insulin-mediated glucose uptake into perfused rat hindlimb. Am J Physiol 1986; 250: E100-E102
16. Lund S, Holman GD, Schmitz O, Pedersen O. Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin. Proc Natl Acad Sci USA 1995; 92: 5817-5821
17. Welsh GI, Hers I, Berwick DC, Dell G, Wherlock M, Birkin R, Leney S, Tavare JM. Role of protein kinase B in insulin-regulated glucose uptake. Biochem Soc Trans 2005; 33: 346-349
18. Lund S, Holman GD, Schmitz O, Pedersen O. Glut 4 content in the plasma membrane of rat skeletal muscle: comparative studies of the subcellular fractionation method and the exofacial photolabelling technique using ATB-BMPA. FEBS Lett 1993; 330: 312-318
19. Marquie G, El Madani T, Solera ML, Duhault J, Espinal J, Khallayoun S, Bennani N. S15261, a novel agent for the treatment of insulin resistance. Studies on Psammomys obesus. Life Sci 1997; 61: 1741-1753
20. Russell JC, Ravel D, Pegorier JP, Delrat P, Jochemsen R, O'Brien SF, Kelly SE, Davidge ST, Brindley DN. Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. J Pharmacol Exp Ther 2000; 295: 753-760
21. Duhault J, Lacour F, Boulanger M, Della-Zuana O, Ravel D, Wierzbicki M, Espinal J. S15261, a new compound for the treatment of the insulin resistance syndrome. Diabetologia 1994; 37: 969-975
22. Henquin JC, Garrino MG, Nenquin M. Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibenclamide: structural requirements and cellular mechanisms. Eur J Pharmacol 1987; 141: 243-251
23. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30: 1000-1007
24. Armstrong RB, Phelps RO. Muscle fiber type composition of the rat hindlimb. Am J Anat 1984; 171: 259-272
25. Nesher R, Karl IE, Kaiser KE, Kipnis DM. Epitrochlearis muscle. 1. Mechanical performance, energetics, and fiber composition. Am J Physiol 1980; 239: E454-E460
26. Wojtaszewski JF, Hansen BF, Urso B, Richter EA. Wortmannin inhibits both insulin- and contraction-stimulated glucose uptake and transport in rat skeletal muscle. J Appl Physiol 1996; 81: 1501-1509
27. Lund S, Flyvbjerg A, Holman GD, Larsen FS, Pedersen O, Schmitz O. Comparative effects of IGF-I and insulin on the glucose transporter system in rat muscle. Am J Physiol 1994; 267: E461-E466
28. Tsao TS, Li J, Chang KS, Stenbit AE, Galuska D, Anderson JE, Zierath JR, MacCarter RJ, Charron MJ. Metabolic adaptations in skeletal muscle overexpressing GLUT4: effects on muscle and physical activity. FASEB J 2001; 15: 958-969
29. Brozinick Jr JT, MacCoid SC, Reynolds TH, Nardone NA, Hargrove DM, Stevenson RW, Cushman SW, Gibbs EM. GLUT4 overexpression in db/db mice dose-dependently ameliorates diabetes but is not a lifelong cure. Diabetes 2001; 50: 593-600
30. Daugaard JR, Richter EA. Relationship between muscle fibre composition, glucose transporter protein 4 and exercise training: possible consequences in non-insulin-dependent diabetes mellitus. Acta Physiol Scand 2001; 171: 267-276
31. Cortez MY, Torgan CE, Brozinick Jr JT, Ivy JL. Insulin resistance of obese Zucker rats exercise trained at two different intensities. Am J Physiol 1991; 261: E613-E619
32. Pruett ED, Oseid S. Effect of exercise on glucose and insulin response to glucose infusion. Scand J Clin Lab Invest 1970; 26: 277-285
33. Nyholm B, Qu Z, Kaal A, Pedersen SB, Gravholt CH, Andersen JL, Saltin B, Schmitz O. Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes 1997; 46: 1822-1828
34. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174
35. Jessen N, Pold R, Buhl ES, Jensen LS, Schmitz O, Lund S. Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in tat muscles. J Appl Physiol 2003; 94: 1373-1379
36. Fujii N, Jessen N, Goodyear LJ. AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab 2006; 291: E867-E877